Mozhgan Jahani
Overview
Explore the profile of Mozhgan Jahani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jahani M, Yarani R, Rezazadeh D, Tahmasebi H, Hoseinkhani Z, Kiani S, et al.
Curr Cancer Drug Targets
. 2024 Apr;
25(3):257-269.
PMID: 38584530
Background: Doxorubicin (DOX) is a chemotherapy drug that is widely used in cancer therapy, especially in Triple-Negative Breast Cancer (TNBC) patients. Nevertheless, cytoprotective autophagy induction by DOX limits its cytotoxic...
2.
Alizadeh S, Majidi J, Jahani M, Esmaeili Z, Nokhbedehghan Z, Ahovan Z, et al.
Biotechnol Bioeng
. 2024 Jan;
121(4):1453-1464.
PMID: 38234099
An ideal antibacterial wound dressing with strong antibacterial behavior versus highly drug-resistant bacteria and great wound-healing capacity is still being developed. There is a clinical requirement to progress the current...
3.
Jahani M, Dokaneheifard S, Mansouri K
J Inflamm (Lond)
. 2020 Nov;
17:33.
PMID: 33139969
COVID-19, disease caused by the new coronavirus, SARS-CoV-2, appeared in the end of 2019 and was rapidly spread in most countries. This respiratory virus has different symptoms from moderate to...
4.
Jahani M, Rezazadeh D, Mohammadi P, Abdolmaleki A, Norooznezhad A, Mansouri K
Adv Pharm Bull
. 2020 Oct;
10(4):490-501.
PMID: 33072530
Blood vessel development is one of the most prominent steps in regenerative medicine due to the restoration of blood flow to the ischemic tissues and providing the rapid vascularization in...
5.
Rezazadeh D, Norooznezhad A, Mansouri K, Jahani M, Mostafaie A, Mohammadi M, et al.
Onco Targets Ther
. 2020 Jun;
13:4239-4247.
PMID: 32547058
Background: Rapamycin has been known as an anti-cancer agent that affects different malignancies such as glioblastoma and prostate cancer. However, there are few studies concerning rapamycin effects on the cervical...
6.
Jahani M, Shahlaei M, Norooznezhad F, Miraghaee S, Hosseinzadeh L, Moasefi N, et al.
Arch Med Res
. 2020 Feb;
51(1):41-53.
PMID: 32086108
Background And Aims: HIF-1 is an important factor that play critical roles in metabolic and metastasis activity of cancer cells. HIF-1 activity can have regulated by TSGA10. Although decreased metastatic...
7.
Jahani M, Azadbakht M, Rasouli H, Yarani R, Rezazadeh D, Salari N, et al.
Food Chem Toxicol
. 2018 Nov;
123:399-411.
PMID: 30423404
Reducing the adverse effects of chemotherapy on normal cells such as endothelial cells is a determinant factor of treatment success especially in pregnant women. In this regard, modulatory effect of...
8.
Jahani M, Noroznezhad F, Mansouri K
Biomed Pharmacother
. 2018 Mar;
102:594-601.
PMID: 29597093
Numerous antitumor therapies have been developed based on the differences in cells' metabolisms. Regarding the important role of arginine (Arg) in the regulation of multiple metabolic and signaling pathways, its...
9.
Jahani M, Azadbakht M, Norooznezhad F, Mansouri K
Biomed Pharmacother
. 2017 Jan;
88:114-123.
PMID: 28103504
Chemoresistance in breast cancer is a major obstacle, especially in p53 mutation types. The aim of this study was to evaluate if a combination therapy of l-arginine with 5-fluorouracil (5-FU)...